| Trial ID # | NCT02345265 |
| Phase | II |
| Drug Class | DNA Damage Repair Pathway Inhibitors: PARP |
| Drug Name | Olaparib |
| Alternate Drug Names | AZD2281, Lynparza |
| Drugs in Trial | Cediranib, Olaparib |
| Eligible Participant | Recurrent high grade serous or high grade endometrioid ovarian cancer |
| Patients Enrolled | 70, 35 Pt-S; median 2 prior therapies |
| Therapy Setting | Recurrence |
| Study Design | Open-Label, Non-randomized |
| Endpoints | ORR, DCR, evaluated per RECIST |
| Biomarkers | Exploratory: gBRCA1/2 |
| Efficacy | ORR: 74.3% (3CR, 23PR, n=35) Exploratory analysis gBRCA status: |
| Clinically Significant Adverse Events | Grade 3/4 AE: hypertension (18%) |
| Conclusion | Olaparib+cediranib is effective independent of gBRCA status |
| Reference | Liu JF et al. A phase 2 biomarker trial of combination cediranib and olaparib in relapsed platinum (plat) sensitive and plat resistant ovarian cancer (ovca). J Clin Oncol (2018) 36 (suppl; abstr 5519) |
Starting
January 1, 2025,
Clearity is joining
Ovarian Cancer
Research Alliance
(OCRA) and this website
will be redirected to
www.ocrahope.org
OCRA and Clearity are committed to serving the ovarian cancer community and providing the education, information, and support people need.